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Graft failure is a significant cause of morbidity and mortality after hematopoietic stem cell transplantation
(HSCT). We used a nonmyeloablative conditioning regimen consisting of the lympho-depleting humanized
CD52-antibody Campath-1H and fludarabine to rescue 12 consecutive children age 9 months to 17 years
with engraftment failure after initial myeloablative HSCT. Primary diagnoses included lymphohematologic
malignancies (n5 6), severe combined immunodeficiency syndrome (SCID) (n5 4), and metabolic diseases
(n 5 2). The same stem cell donor was used as for the primary graft: mismatched family member (n 5 7),
matched unrelated donor (n5 4), or matched related donor (n5 1). The patients received doses of CD341
cells that did not significantly differ from those used in the initial, failed transplant. At a median follow-up of 51
months (range, 4 to 84 months), 6 of 6 patients with nonmalignant diseases and 4 of 6 patients with malig-
nancy were alive. Two patients died, 1 patient from pulmonary toxicity and 1 from relapse, at 51 days and 8
months posttransplantation, respectively. All 12 patients initially achieved sustained neutrophil engraftment
and complete donor chimerism by day 28. Six patients received donor lymphocyte infusion (DLI) after ‘‘res-
cue’’ therapy to maintain donor chimerism. At 6 months, 4 patients had complete donor cell engraftment, 4
had 15% to 89% stable donor chimerism, and 3 had developed secondary graft failure. This conditioning reg-
imen was generally well tolerated; 4 of the 12 patients never became neutropenic, and 9 never became
thrombocytopenic. Only 1 patient developed graft-versus-host disease (GVHD; grade 1), and none had
chronic GVHD. Thus, the regimen that we describe can be usedwith minimal toxicity to effectively overcome
graft failure after myeloablative HSCT in children.
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Nonengraftment after receipt of fullymyeloablative
conditioning is a grave complication of hematopoietic
stem cell transplantation (HSCT). Patients suffer
from prolonged pancytopenia and immunosuppres-
sion, and this condition is often fatal, usually due
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doi:10.1016/j.bbmt.2008.09.003to overwhelming infection [1]. Repeat conditioning
with fully ablative preparative regimens produces
unacceptable organ toxicity; thus, submyeloablative
HSCT represents an attractive and less toxic means
of rescue. By permitting progressive and often com-
plete donor engraftment, submyeloablative HSCT
also helps patients avoid the period of aplasia associ-
ated with more intensive myeloablative regimens.
A major problem associated with submyeloablative
conditioning has been an increase in engraftment
failure, reportedly ranging between 5% and 30%,
compared with 1% to 5% after fully ablative regi-
mens [2-4]. Such a high prevalence of graft failure
is of concern for patients who have already rejected
their first stem cell allograft.
Graft failure usually is attributed to inadequate
suppression of the host immune system, which permits
the development of a host antidonor cellular immune
response and consequent rejection of donor hemato-
poietic cells [5]. In an effort to prevent this
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cytolytic antibodies to deplete the host cellular
immune responses before transplantation. Incorpora-
tion of antithymocyte globulin (ATG) in conditioning
regimens effectively prevents rejection in high-risk
patients [6,7]. Similarly, the humanized monoclonal
antibody (MAb) Campath-1H (alemtuzumab) can act
as a lymphodepleting antibody by targeting CD52,
a nonmodulating glycosyl-phospahatidyl-inositol–
anchored protein. This MAb depletes almost all T
and B lymphocytes and the majority of monocytes,
macrophages, eosinophils, natural killer cells, and
dendritic cells, because these also express the target
antigen [8-14]. The use of these lymphocytolytic anti-
bodies has made primary engraftment rates after
submyeloablative conditioning regimens comparable
to those after myeloablative HSCT [15,16]. Whether
the benefits of these regimens would extend to pro-
ducing engraftment once ablative stem cell transplan-
tation has failed remains unclear, however.
We have tested the safety and efficacy of Campath-
1H as part of a subablative fludarabine-based condi-
tioning regimen for patients with engraftment failure
after ‘‘conventional’’ myeloablative allogeneic HSCT.
METHODS
Study Patients
The study protocol was approved by Baylor Col-
lege of Medicine Institutional Review Board. Between
September 2000 and March 2007, we prospectively
evaluated a submyeloablative reengraftment protocol
in 12 patients who sustained graft failure after myeloa-
blative allogeneic stem cell transplantation from an
HLA-matched related (n5 1) or an HLA-mismatched
related (n 5 7) donor, or from a matched unrelated
donor (n 5 4) (Table 1). Donors were matched for
HLA-A, -B, -C, -DRB1, and -DQB1 by intermediate-
or high-resolution DNA-typing techniques. Patients
were eligible if the initial stem cell donor was able to
give a second stem cell dose, but were excluded if
they had uncontrolled intercurrent infection or refrac-
tory actue myelogenous leukemia (AML) or acute
lymphoblastic leukemia (ALL), or chronic myeloge-
nous leukemia in blast crisis.
Conditioning Regimen, GVHD Prophylaxis, and
Stem Cell Source
The conditioning regimen for the rescue trans-
plant consisted of Campath-1H in a patient weight–
dependent dose (\ 15 kg: 3 mg i.v. daily, total dose
12 mg; 15 to 30 kg: 5 mg i.v. daily, total dose 20 mg;
. 30 kg: 10 mg i.v. daily, total dose 40 mg) and fludar-
abine 30mg/m2 daily (total dose, 120mg/m2) from day
-5 to day -2 from stem cell infusion. Patients were pre-
medicated before Campath-1H infusion, to prevent al-lergic reactions. GVHD prophylaxis consisted of
FK506 administered from day -2 and continued
up to 6 months posttransplantation. Acute and
chronic GVHD were graded according to standard
criteria [17]. After transplantation, granulocyte col-
ony-stimulating factor, 5 mg/kg/day, was adminis-
tered subcutaneously from day 17 until the
granulocyte count was .1000/mL.
Analysis of Donor Chimerism and Donor
Lymphocyte Infusion
Donor engraftment was evaluated on days 28, 60,
100, 180, and 365 posttransplantation. Chimerism
studies were assessed by means of polymerase chain re-
action analysis of informative minisatellite regions
(short tandem repeat loci) or by fluorescent in situ hy-
bridization for X and Y chromosomes in the event of
sex-mismatched transplantation.
When decreasing chimerism was revealed on 2
consecutive studies, the patient received donor lym-
phocyte infusion (DLI), unless there was active
GVHD. Escalating doses of CD31 lymphocytes
were administered, starting at a dose of 1  105 T
cells/kg and increasing up to 1  107 T cells/kg if no
improvement in chimerism was seen for at least 4
weeks after the start of infusion.
Table 1. Baseline characteristics of patients (n512)
Characteristic Value
Median age, months (range) 17 (9 months-17 years)
Sex (male/female) 8/4
Primary diagnosis, number of patients (%)
Lympho hematologic malignancy 6 (50)
Immunodeficiency syndrome 4 (33)
Metabolic disease 2 (17)
Median duration from diagnosis, months (range) 10 (1-26)
Previous transplant
Type of conditioning, number of patients (%)
Myeloablative conditioning 12 (100)
More than one previous transplant 2 (17)
Median duration from previous transplant,
months (range)
2 (1-10)
Stem cell dose: median CD34+  10e6 cells/
kg (range)
7.14 (2.8-37.1)
Current transplant:
Type of Donor, number of patients (%)
Mismatched related 7 (58)
Matched unrelated 4 (34)
Matched related 1 (8)
Stem cell source, number of patients (%)
Peripheral blood 11 (92)
Bone marrow 1 (8)
Stem cell dose
Peripheral blood donors: median CD34+
 10e6 cells/kg (range)
15.1 (0.3-29.4)
Bone marrow donor: TNC  10e8 cells/kg 38
CMV serostatus, number of patients (%)
Donor or recipient positive 10 (83)
Both negative 2 (17)
Median time to follow-up, months (range) 51 (4-84)
TNC indicates total nucleated cells.
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All patients received standard nursing and
supportive care according to institutional proto-
cols. Infection prophylaxis always included an anti-
fungal agent (generally fluconazole), acyclovir, and
co-trimoxazole.
Definitions and Statistical Analysis
For all patients, primary graft failure was defined as
failure to maintain absolute neutrophil count $ 500/
mL for 3 consecutive days after allogeneic HSCT. Sec-
ondary graft failure was defined as failure to sustain an
absolute neutrophil count $ 500/mL after attainment
of primary engraftment or failure to sustain platelet
count $ 20,000/mL despite neutrophil engraftment.
For patients with SCID, graft failure was defined as
failure to recover $ 500/mm3 T cells and/or failure
to generate satisfactory response to in vitro mitogen
stimulation. T cell function was tested at the earliest
signs of granulocyte engraftment, then every 4 to 6
weeks thereafter. For patients with genetic diseases,
engraftment failure was defined as a level of donor chi-
merism insufficient to correct the genetic or metabolic
deficiency.
Mortality was the primary endpoint of this study.
Secondary endpoints were hematopoietic engraft-
ment; regimen-related toxicity, including infection-
related death; and acute and/or chronic GVHD.
RESULTS
Patient Characteristics
Between September 2000 and March 2007, 12
patients (median age, 17 months; range, 9 months
to 17 years; 8 males) with engraftment failure were
enrolled in the study (Table 1). All patients had pre-
viously undergone 1 or more transplantations for
a hematologic malignancy (n 5 6), an immunodefi-
ciency syndrome (n 5 4), or a metabolic disease
(n 5 2). All 12 patients had failed to engraft after
a previous myeloablative HSCT, and 2 had failed
to engraft after 2 failed ablative transplantations be-
fore enrollment on this protocol. The transplant was
from an antigen-mismatched family donor (MMRD)
in 7 patients, from a matched unrelated donor
(MUD) in 4 patients, and from an HLA-identical
sibling (MRD) in 1 patient. The median number
of blood CD341 cells infused for the initial trans-
plantation was 7.14  106 cells/kg recipient body
weight (range, 2.8 to 37.1  106 cells/kg).
For all 12 patients, the hematopoietic stem cells
were obtained from the same donors whose cells had
failed to engraft after myeloablative transplantation.
Eleven patients received unmanipulated peripheral
blood HSCT, whereas 1 patient received unmanipu-
lated bone marrow HSCT. A median of 15.1  106CD34 cells/kg recipient body weight (range, 0.3 to
29.4  106 cells/kg) was infused. For the single recip-
ient of bone marrow, the number of total nucleated
cells infused was 38  108 cells/kg recipient body
weight. These cell numbers were comparable to those
used for the primary, failed transplant (P 5 .23).
Engraftment, Donor Chimerism, and Donor
Lymphocyte Infusion
All evaluable patients achieved neutrophil engraft-
ment and donor chimerism by day 28 (Table 2). Four
patients (33%) never became neutropenic (neutrophils
\ 0.5  109/L), and 9 patients (75%) never became
thrombocytopenic (platelets\ 50  109/L). For those
with neutropenia or thrombocytopenia, the median
intervals to neutrophil recovery (. 0.5  109/L) and
platelet recovery (. 20  109/L) were 12 days (range, 3
to 20 days) and 17 days (range, 2 to 42 days), respectively.
At amedian of 16 days after transplantation, all evaluable
patients had evidence of donor cell engraftment.
Six patients (patients 1, 2, 6, 7, 8, and 10) received
DLI for progressive loss of donor cell chimerism after
initial engraftment (Table 2). Of these 6 patients, 2
subsequently achieved full donor chimerism (patients
1 and 2), 2 developed secondary graft failure (patients
6 and 7), and 2 developed mixed stable chimerism
(patients 8 and 10). Patient 6 eventually received a third
transplant from a 6/6 HLA MUD after conditioning
with Campath-1H and fludarabine, in the same doses
used for this rescue protocol, along with 450 cGy of
total body irradiation, and maintained full donor chi-
merism more than 60 months after HSCT.
GVHD
Although a higher incidence of (delayed) acute
GVHD has been associated with submyeloablative
transplantation, only 1 patient in our series developed
acute GVHD, and only at grade 1. Of note, no patient
who subsequently received DLI sustained GVHD.
Eleven patients (91%) survived beyond day 100, and
none developed chronic GVHD.
Infections
Nonfatal viral and fungal infections are detailed in
Table 3. Ten (83%) patients were either cytomegalo-
virus (CMV)-positive at the time of transplantation
or received stem cells from CMV-positive donors.
Three of these patients reactivated CMV, but none
progressed to CMV disease (Table 3).
Disease Response, Survival, and Mortality
At a median follow-up of 51 months (range, 4 to 84
months), 10 of the 12 patients survived (83%). All 6
HSCT recipients with a nonmalignant primary diag-
nosis survived (patients 1-5 with corrected genetic or
metabolic deficiency; patient 6 needed a third
Table 2. Engraft
Patient
Age
(months)
ons
tion day)
DLI
CD3+
cell dose (k/g)
Chimerism
after 6
months (%)
Acute-GVHD
(grade)
Outcome
(cause of death)
Primary Immunod
1 15 SC 810e3 100 No Alive
2 10 X- 510e4 100 No Alive
3 9 SC 100 No Alive
4 4 years SC 15 No Alive
Metabolic Disease
5 13 I-c 60 No Alive
6 19 H 610e4 0 No Alive
Hematological Ma
7 11 F- 108) 110e7, 610e7, 110e8 0 No Alive
8 15 F- 2) 510e6, 410e5 38 No Alive
9 20 H 2 No Alive
10 4 years R- 2, 158) 310e5, 510e5, 110e6,
510e6
89 No Alive
11 17 years T- NA No Died, pulmonary (T)
12 7 years AM 100 No Died, relapse
X-SCID, X-linked se ll acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; T-, T lymphcyte
deficient; B -, B lym a, interleukin 7 receptor alpha chain; IL2Rg, interleukin 2 receptor gamma chain;
MMRD, mismatched , acute graft versus host disease; (T), possibly treatment-related.
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Diagnosis
SCID
phenotype
(genotype)
Donor
type
Mismatched
locus
CD34+ cell
number
(10e6/kg)
Engrafted
at day 28
Days to
engraftment
DLI infusi
(posttransplanta
eficiency
ID T-, B + NK +
(IL7R a mutation)
MMRD A, B, DRB1 17.9 Yes 20 1 (51)
SCID T-, B-, NK +
(unknown)
MMRD Haploidentical* 0.3 Yes 8 1 (84)
ID T-, B+, NK lo
(IL2Rg mutation)
MMRD A, B, DRB1 29.4 Yes 14 0
ID T lo, B lo, NK hi
(unknown)
MUD N/A 23.8 Yes 17 0†
ell disease N/A MUD N/A 12.9 Yes 3 0†
urler disease N/A MUD N/A 26.5 Yes 6 1 (26)
lignancy
HLH N/A MRD N/A 4.7 Yes Never, drop<500 3 (49, 73,
HLH N/A MUD N/A 20.7 Yes 16 2 (74, 10
LH N/A MMRD B, DRB1 9.6 Yes Never, drop<500 0
ALL N/A MMRD A, B, DRB1 8.3 Yes Never drop<500 4 (28, 69, 11
ALL (HR) N/A MMRD A 16.4 Yes Never, drop<500 0†
L N/A MMRD B 13.8 Yes 11 0
vere combined immunodeficiency; F-HLH, familial hemophagocytic lymphohistiocytosis; R, relapsed; T-ALL, T ce
phcyte deficient; NK-, cell deficient; T +, T lymphcyte positive; B +, B lymphocyte positive; lo, low; hi, hight; IL7R
related donor; MUD, matched unrelated donor; MRD, matched related donor; NA, not applicable; a-GVHD
nor, and details of mismatch not available.
d stable chimerism.
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Infection
Patient Viral Fungal (site)
Primary Immunodeficiency
1 ACENO; PICO Candida albicans (mouth)
2 Candida albicans (mouth)
3 HSV
4 CMV
Metabolic Disease
6 CMV
7 ROTA Pneumocystis carinii (lung)
Hematological Malignancy
9 HSV Aspergillus fumigatus (spinal cord)
10 RSV
12 CMV
ADENO, adenovirus; PICO, picovirna virus family; HSV, herpes simplex virus; CMV, cytomegalovirus; ROTA, rotavirus; PIV, parainfluenza virus.HSCT), as did 4 of 6 patients who underwent initial
HSCT for malignant disease (all in complete remis-
sion). Both deceased patients (patients 11 and 12)
had received MMRD transplants. Patient 11 was
a 17-year-old male with T cell ALL who developed
a febrile illness and progressive pulmonary infiltrates
and eventually died of respiratory failure on posttrans-
plantation day 51 (Table 2). This could have been
related to an alloimmune reaction, such as bronchio-
litis obliterans or bronchiolitis obliterans with orga-
nizing pneumonia, but the clinical suspicion was
never confirmed. Patient 12 was a 7-year-old female
patient who died with relapsed AML 8 months after
HSCT.
DISCUSSION
We have shown that submyeloablative condition-
ing with Campath-1H and fludarabine can allow suc-
cessful donor stem cell engraftment after a failed
myeloablative allograft from the same donor. Al-
though maintenance of donor chimerism required
DLI in half of the patients treated, none developed
significant acute or chronic GVHD, and treatment-
related mortality was low, with 10 of 12 patients sur-
viving between more than 4 months and more than
84 months.
There is no completely satisfactory approach for
patients who experience allograft failure after primary
myeloablative HSCT. A second myeloablative trans-
plant from the same or a different donor is associated
with treatment-related mortality rates of up to 80%
and thus is now usually avoided [18,19]. An alternative
possibility is retransplantation after nonmyeloablative
conditioning regimens. When used in primary trans-
plantation, these submyeloablative regimens have al-
lowed engraftment while limiting regimen-related
morbidity and mortality [3,20,21]. Unfortunately,
their use has beenmarred by a high rate of engraftment
failure, particularly when donor and recipient areHLA-mismatched [4,15,22]. The addition of anti-T
cell antibodies such as ATG to submyeloablative
transplantation has helped increase engraftment rates
[6,7] after submyeloablative conditioning [15,16], al-
beit at the cost of an increased incidence of infectious
deaths [23,24]. For example, Chewning et al. [25] re-
ported consistent engraftment when submyeloablative
transplantation using fludarabine and ATG were used
in 16 patients (age 4 to 59 years) with marrow failure,
but despite high doses of CD341 cells, 6 patients died
of infection.
We and others have substituted Campath-1H for
ATG as a component of first submyeloablative trans-
plantation [26-30]. This CD52-directed monoclonal
antibody is well tolerated and may eliminate a broader
range of host immune system cells compared with
ATG. Kottaridis et al. [31] reported sustained engraft-
ment in 42 of 44 patients (median age, 41 years) with
hematologic malignancies receiving aMRD transplant
after Campath-1H, fludarabine, and melphalan condi-
tioning. In another study by the same group involving
patients receiving MUD transplants using the same
regimen, 45 of 47 patients (median age, 47 years) sus-
tained neutrophil engraftment at a median of 13 days
posttransplantation [26,31].
We have now successfully extended the foregoing
approach to patients whose primary, ablative trans-
plantation failed. Because we used the same donor
and stem cell dose, differences in the stem cell source
and the CD341 progenitor number alone cannot ac-
count for successful secondary engraftment, which in-
stead can be attributed to depletion of host rejection
mechanisms by the combination of fludarabine and
Campath-1H. Moreover, persistence of the Cam-
path-1H during the posttransplantation period may
have helped remove donor-derived alloreactive donor
T cells, thereby explaining the low incidence of acute
and chronic GVHD [26,31]. Despite initial successful
full donor engraftment, mixed chimerism subse-
quently appeared in half of our patients; however,
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of these 6 patients [32,33].
Although our conclusions are limited by the small
number of evaluable patients, the combination of
Campath-1H and fludarabine with reinfusion of donor
stem cells appears to be an attractive therapeutic
option for patients with graft failure after myeloabla-
tive conditioning. It will be interesting to see whether
these initially encouraging results can be sustained in
larger series and at other centers.
ACKNOWLEDGMENTS
We thank James Arce for his assistance with data
management.
REFERENCES
1. Davies SM, Weisdorf DJ, Haake RJ, et al. Second infusion of
bone marrow for treatment of graft failure after allogeneic
bone marrow transplantation. Bone Marrow Transplant. 1994;
14:73-77.
2. Khouri IF, Keating MJ. High-dose chemotherapy for chronic
lymphocytic leukemia: eligibility, timing, and benefit? Ann
Oncol. 1998;9:131-132.
3. Khouri IF, KeatingM,KorblingM, et al. Transplant-lite: induc-
tion of graft-versus-malignancy using fludarabine-based nona-
blative chemotherapy and allogeneic blood progenitor cell
transplantation as treatment for lymphoid malignancies. J Clin
Oncol. 1998;16:2817-2824.
4. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to conven-
tional bone marrow transplantation with lethal cytoreduction
for the treatment of malignant and nonmalignant hematologic
diseases. Blood. 1998;91:756-763.
5. SimpsonD. T-cell depleting antibodies: new hope for induction
of allograft tolerance in bonemarrow transplantation? BioDrugs.
2003;17:147-154.
6. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of
T-cell–depleted haploidentical ‘‘three-loci’’ incompatible trans-
plants in leukemia patients by addition of recombinant human
granulocyte colony-stimulating factor–mobilized peripheral
blood progenitor cells to bone marrow inoculum. Blood. 1994;
84:3948-3955.
7. Storb R, Blume KG, O’Donnell MR, et al. Cyclophosphamide
and antithymocyte globulin to condition patients with aplastic
anemia for allogeneic marrow transplantations: the experience
in four centers. Biol Blood Marrow Transplant. 2001;7:39-44.
8. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G
causes rapid depletion of circulating host dendritic cells (DCs)
before allogeneic transplantation but does not delay donor DC
reconstitution. Blood. 2002;99:2586-2591.
9. Riechmann L, Clark M, Waldmann H, et al. Reshaping human
antibodies for therapy. Nature. 1988;332:323-327.
10. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on
human hematopoietic progenitors in vitro. Blood. 1993;82:
807-812.
11. Wing MG, Waldmann H, Isaacs J, et al. Ex-vivo whole blood
cultures for predicting cytokine-release syndrome: dependence
on target antigen and antibody isotype. Ther Immunol. 1995;2:
183-190.
12. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-
dose cytokine-release syndrome by CAMPATH 1-H: involve-
ment of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on
NK cells. J Clin Invest. 1996;98:2819-2826.13. Rowan W, Tite J, Topley P, et al. Cross-linking of the CAM-
PATH-1 antigen (CD52) mediates growth inhibition in human
B- and T-lymphoma cell lines, and subsequent emergence of
CD52-deficient cells. Immunology. 1998;95:427-436.
14. Dyer MJ, Hale G, Hayhoe FG, et al. Effects of CAMPATH-1
antibodies in vivo in patients with lymphoid malignancies: influ-
ence of antibody isotype. Blood. 1989;73:1431-1439.
15. Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor
graft failure with nonmyeloablative conditioning of fludarabine,
antithymocyte globulin and a second allogeneic hematopoietic
transplantation. Bone Marrow Transplant. 2007;40:431-435.
16. Strahm B, Locatelli F, Bader P, et al. Reduced-intensity condi-
tioning in unrelated donor transplantation for refractory cytope-
nia in childhood. Bone Marrow Transplant. 2007;40:329-333.
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
Conference on Acute GVHDGrading. BoneMarrow Transplant.
1995;15:825-828.
18. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow
transplantation in patients who relapse after autologous trans-
plantation. Bone Marrow Transplant. 1997;20:859-863.
19. Ringden O, Labopin M, Frassoni F, et al. Allogeneic bone mar-
row transplant or second autograft in patients with acute leuke-
mia who relapse after an autograft. Acute Leukaemia Working
Party of the EuropeanGroup for Blood andMarrowTransplan-
tation (EBMT). Bone Marrow Transplant. 1999;24:389-396.
20. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic
hematopoietic progenitor cells with purine analog–containing
chemotherapy: harnessing graft-versus-leukemia without mye-
loablative therapy. Blood. 1997;89:4531-4536.
21. Giralt S, Thall PF,Khouri I, et al.Melphalan and purine analog–
containing preparative regimens: reduced-intensity condition-
ing for patients with hematologic malignancies undergoing
allogeneic progenitor cell transplantation. Blood. 2001;97:
631-637.
22. Hows JM. Mechanisms of graft failure after human marrow
transplantation: a review. Immunol Lett. 1991;29:77-80.
23. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte
globulin for graft-versus-host disease prophylaxis in transplants
from unrelated donors: 2 randomized studies fromGruppo Ital-
iano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):
2942-2947.
24. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin
prevents chronic graft-versus-host disease, chronic lung dys-
function, and late transplant-related mortality: long-term fol-
low-up of a randomized trial in patients undergoing unrelated
donor transplantation. Biol Blood Marrow Transplant. 2006;12:
560-565.
25. Chewning JH, Castro-MalaspinaH, Jakubowski A, et al. Fludar-
abine-based conditioning secures engraftment of second
hematopoietic stem cell allografts (HSCT) in the treatment of
initial graft failure. Biol Blood Marrow Transplant. 2007;13:
1313-1323.
26. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplanta-
tion-relatedmortality following unrelated donor stem cell trans-
plantation by using a nonmyeloablative conditioning regimen.
Blood. 2002;99:1071-1078.
27. Hale G, Waldmann H. Risks of developing Epstein-Barr virus–
related lymphoproliferative disorders after T-cell–depleted
marrow transplants. CAMPATH Users. Blood. 1998;91:
3079-3083.
28. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable
outcomes of matched-related and alternative donor stem cell
transplantation for pediatric severe aplastic anemia. Biol Blood
Marrow Transplant. 2006;12:1277-1284.
29. Popat U, CarrumG,May R, et al. CD52 and CD45monoclonal
antibodies for reduced-intensity hemopoietic stem cell trans-
plantation from HLA-matched and one antigen-mismatched
unrelated donors. Bone Marrow Transplant. 2005;35:1127-1132.
30. Popat U, Heslop HE, Durett A, et al. Outcome of reduced-in-
tensity allogeneic hematopoietic stem cell transplantation
(RISCT) using antilymphocyte antibodies in patients with
1304 Biol Blood Marrow Transplant 14:1298-1304, 2008N. Ahmed et al.high-risk acute myeloid leukemia (AML). Bone Marrow Trans-
plant. 2006;37:547-552.
31. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAM-
PATH-1H prevents graft-versus-host disease following non-
myeloablative stem cell transplantation. Blood. 2000;96:
2419-2425.
32. Frassoni F, Strada P, Sessarego M, et al. Mixed chimerism after
allogeneic marrow transplantation for leukaemia: correlationwith dose of total body irradiation and graft-versus-host disease.
Bone Marrow Transplant. 1990;5:235-240.
33. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive
immunotherapy evaluating escalating doses of donor leuko-
cytes for relapse of chronic myeloid leukemia after bone
marrow transplantation: separation of graft-versus-leukemia
responses from graft-versus-host disease. Blood. 1995;86:
1261-1268.
